BACTERIOPHAGE THERAPY IN HOSPITALS: UNVEILING THE POTENTIAL OF RIVER GANGA BACTERIOPHAGES

Main Article Content

Ankur Kumar
Ganesh Kumar Verma
Avinash Bairwa
Priyanka Singh
Nikita Deshwal
Ashish Kothari
Jitender Gairolla
Priyanka Naithani
Shivashish Dobhal
Prashant Kumar
Narayanan Mp
Balram Ji Omar

Keywords

Bacteriophages, Alternatives of antibiotics, Phage therapy, Phage cocktail, Multidrug resistant, Bacterial infection

Abstract

Abstract- Bacteriophages are viruses that consume bacteria; these viruses proliferate in Ganga water and have been proven to be more efficacious in treating both acute and chronic human infections in the hospitals settings and also in certain ongoing studies. The goal of the research is to isolate new bacteriophages, which could be the most effective alternative to the antibiotics. The antibiotics have lost their effectiveness in treating bloodstream infections, urinary tract infections, burns, surgical site infections, pneumonia, bed sores, and diabetic foot ulcers etc. The Ganga River is recognized to be a major source of bacteriophages. It contains a variety of bacteriophages. Numerous research institutes in India and elsewhere studied Ganga water samples taken from various ghats or sites. They discovered that one of the bacteriophages in the river Ganga has the ability to fight drug-resistant diseases in humans brought on by Pseudomonas aeruginosa. Numerous studies conducted in the last few years have shown that antibiotics, such as ceftazidime, imipenem, and amikacin, are inefficient at curing infections i.e. bacteria are becoming resistant to antibiotics, known as antimicrobial resistance AMR, presently a huge global concern. Also, the presence of MDR, Amp-C traits and ESBL bacteria are confirmed in the water of Ganges. Therefore, there will be high chances to find bacteriophages against these resistant bacteria’s. As it presents a problem with fewer antibiotic alternatives and increased treatment costs. Certain bacterial infections have a high death and morbidity rate and are frequently persistent. Some persons with diabetes develop chronic skin sores, necessitating the amputation of affected body parts. The WHO has classified bacteriophage as a priority pathogen as well. This suggests that the development of new antimicrobial medicines needs to be given top priority. According to a review of the literature, as compared to other antibiotic medications that destroy good gut microbiota, bacteriophages in ganga water have not been shown to be side-effects.

Abstract 626 | pdf Downloads 182

References

1. Foster TJ (2017) Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev. 41(3):430-449.
2. Tarsillo B, Priefer R (2020) Proteobiotics as a new antimicrobial therapy. Microb Pathog. 142:104093.
3. Sharma S, Chatterjee S, Datta S, Prasad R, Dubey D, et al. (2017) Bacteriophages and its applications: an overview. Folia Microbiol (Praha). 62(1):17-55.
4. Duckworth DH (1976) Who discovered bacteriophage? Bacteriol Rev. 40(4):793-802.
5. Laemmli UK, Eiserling FA (1968) Studies on the morphopoiesis of the head of phage T-even. Mol Gen Genet. 101(4):333-345.
6. Fischetti VA (2008) Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol. 11(5): 393-400.
7. Hagens S, Loessner MJ (2007) Application of bacteriophages for detection and control of foodborne pathogens. Appl Microbiol Biotechnol. 76(3):513-519.
8. Nandhagopal N, Simpson AA, Gurnon JR, Yan X, Baker TS, et al. (2002) The structure and evolution of the major capsid protein of a large, lipid-containing DNA virus. Proc Natl Acad Sci USA. 99(23):14758-14763.
9. Boyd JSK (1951) Observations on the relationship of symbiotic and lytic bacteriophage. J Pathol Bacteriol. 63(3):445-457.
10. Lu TK, Koeris MS. The next generation of bacteriophage therapy. Current opinion in microbiology. 2011 Oct 1;14(5):524-31.
11. Summers WC (2012) The strange history of phage therapy. Bacteriophage. 2(2):130–133.
12. Sulakvelidze A, Alavidze Z, Morris JG (2001) Bacteriophage therapy. Antimicrob Agents Chemother. 45(3):649–659.
13. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage. 1(2):66–85.
14. Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Microbiol. 128(2):307-318.
15. Smith HW, Huggins MB (1983) Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbial. 129(8):2659-2675.
16. Smith HW, Huggins MB, Shaw KM (1987) The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol. 133(5):1111-1126.
17. Bogovazova GG, Voroshilova NN, Bondarenko VM (1991) The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol. 4:5-8.
18. Bogovazova GG, Voroshilova NN, Bondarenko VM, Gorbatkova GA, Afanas' eva EV, et al. (1992) Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol. 3:30-33.
19. Soothill JS (1992) Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 37(4):258-261.
20. Soothill JS (1994) Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa Burns. 20(3):209-211.
21. Sulakvelidze A, Alavidze Z, Morris Jr JG. Bacteriophage therapy. Antimicrobial agents and chemotherapy. 2001 Mar 1;45(3):649-59.
22. Nikolich MP, Filippov AA. Bacteriophage therapy: Developments and directions. Antibiotics. 2020 Mar 24;9(3):135.
23. Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. The Journal of Infection in Developing Countries. 2014 Feb 13;8(02):129-36.
24. Petrovic Fabijan A, Lin RC, Ho J, Maddocks S, Ben Zakour NL, Iredell JR, Westmead Bacteriophage Therapy Team Khalid Ali 1 3 Venturini Carola 1 3 Chard Richard 3 7 Morales Sandra 8 Sandaradura Indy 2 3 Gilbey Tim 2. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature microbiology. 2020 Mar 2;5(3):465-72.
25. Mathur MD, Vidhani S, Mehndiratta PL, Bhalla P, Reddy B. Bacteriophage therapy: an alternative to conventional antibiotics. Journal-Association of Physicians of India. 2003 Jun 1;51:593-6.
26. Payne RJ, Jansen VA. Pharmacokinetic principles of bacteriophage therapy. Clinical pharmacokinetics. 2003 Apr;42:315-25.
27. Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annual review of virology. 2015 Nov 9;2:599-618.
28. Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018 Jun 30;10(7):351.
29. Clark JR. Bacteriophage therapy: history and future prospects. Future Virology. 2015 Apr;10(4):449-61.
30. Azeredo J, Sillankorva S. Bacteriophage therapy. Unspecified; 2018

Most read articles by the same author(s)